In this respect, co-administration of an adenoviral vector encoding Flt3L (pAd-Flt3L) and cell lysate of the colon cancer model CT26 into the footpad of the mouse prior to subcutaneous injection at the same location with CT26 resulted in the successful priming of both cDCs and pDCs, enabling tumor regression (120). The gene discussed is FLT3LG; the disease is colonic neoplasm.